Mast Therapeutics preclinical data

In a preclinical model of chronic heart failure, an IV infusion of MST-188 significantly improved left ventricular ejection fraction (LVEF), end systolic volume, stroke volume and cardiac output vs. placebo (p<0.05 for all). Mast said it is developing a Phase II strategy with MST-188 in heart failure and will provide an update on its plans later this year. ...